Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000659666 | SCV000781509 | likely benign | Connective tissue disorder | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001307125 | SCV001496523 | uncertain significance | Heterotopia, periventricular, X-linked dominant; Melnick-Needles syndrome; Oto-palato-digital syndrome, type II; Frontometaphyseal dysplasia | 2020-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 1309 of the FLNA protein (p.Val1309Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FLNA protein function. This variant has not been reported in the literature in individuals with FLNA-related conditions. ClinVar contains an entry for this variant (Variation ID: 547384). This variant is present in population databases (rs782412141, ExAC 0.002%). |
Ambry Genetics | RCV002369782 | SCV002623746 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2017-11-29 | criteria provided, single submitter | clinical testing | The p.V1309I variant (also known as c.3925G>A), located in coding exon 22 of the FLNA gene, results from a G to A substitution at nucleotide position 3925. The valine at codon 1309 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and isoleucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |